Trial Profile
Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients With Relapsed and Refractory Non-Hodgkin Lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 May 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- 19 May 2021 Planned End Date changed from 30 Nov 2020 to 19 May 2025.
- 19 May 2021 Planned primary completion date changed from 30 Nov 2020 to 19 May 2024.
- 27 Jun 2019 Arms are reduced from 4 to 1. Follicular-lymphoma, Diffuse-large-B-cell-lymphoma and T-cell-lymphoma are deleted.